Is Illumina, Inc. (ILMN) a Buy, Sell, or Hold?
Illumina, Inc.
NASDAQ:ILMN
$188.031 USD
-$3.17 (-1.66%)
- Volume
- 447.64K
- Average Volume
- 1.85M
- Market Capitalization
- $28.45B
- P/E Ratio
- 33.94
- Dividend Yield
- 0.00%
- Price Target
- $155.00
- Year High
- $196.66
- Year Low
- $88.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.75
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jacob Thaysen |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | ILMN |
| CUSIP | 452327109 |
| CIK | 0001110803 |
| Web | https://www.illumina.com |
| Phone | 858 202 4500 |
| Currency | USD |
| Employees | 8600 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.95 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.75 |
| Quick Ratio | 1.36 |
| Cash Ratio | 0.70 |
Sales & Book Value
| Annual Sales | $4.34B |
| Price / Sales | 6.48 |
| Cash Flow | 6.46 |
| Price / Cash Flow | 28.77 |
| Price / Book | 10.75 |
Price Target and Rating
| Average Stock Price Forecast | $155.00 |
| High Stock Price Forecast | $200.00 |
| Low Stock Price Forecast | $122.00 |
| Forecast Upside/Downside | 21.31% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 50 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $5.45 |
| Trailing P/E Ratio | 33.94 |
| PEG Ratio | 0.26 |
| P/E Growth | 0.26 |
| Net Income | $850M |
| Net Margin | 19.43% |
| Pretax Margin | 24.16% |
| Return on Equity | 33.99% |
| Return on Assets | 13.01% |
Financials Score
| AltmanZ Score | 5.84 |
| Piotroski Score | 7.00 |
| Working Capital | 1.17B |
| Total Assets | 6.56B |
| Ebit | 1.14B |
| Market Cap | 28.75B |
| Total Liabilities | 3.88B |
Poll Results
About Illumina, Inc. (NASDAQ:ILMN) Stock
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, ... universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
2026-07-09 16:05:00
SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Stocks Look Shaky, But This Sector is Booming (Biotech)
2026-07-09 14:06:06
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know
2026-07-09 13:01:10
Does Illumina (ILMN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?
2026-07-09 11:31:21
ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.
Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat
2026-07-09 11:07:35
Illumina commands 90%+ market share in genomics sequencing, powering a $30B+ TAM growing at double digits with a robust razor-and-blades model. Post-GRAIL, management's renewed focus on core sequencing, cost control, and capital return is driving revenue recovery, margin expansion, and free cash flow. NovaSeq X placements and consumables pull-through are key near-term catalysts; 65%+ of consumables revenue is clinical, supporting high margins and recurring cash flows.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
2026-07-09 10:51:07
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
2026-07-09 09:05:00
New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world.
Beyond Automotive: Healthcare Automation Drives the Next Leg for Robotics ETFs
2026-07-08 15:05:24
Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.
Frequently Asked Questions
-
What is the current Illumina, Inc. (ILMN) stock price?
-
Illumina, Inc.(NASDAQ:ILMN) stock price is $188.031 in the last trading session. During the trading session, ILMN stock reached the peak price of $196.66 while $88 was the lowest point it dropped to. The percentage change in ILMN stock occurred in the recent session was --1.66% while the dollar amount for the price change in ILMN stock was -$-3.17.
-
ILMN's industry and sector of operation?
-
The NASDAQ listed ILMN is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of ILMN?
-
Jacob Thaysen | CEO, Interim Chief Commercial Officer & Director
Ankur Dhingra | Chief Financial Officer
Mark Field | Chief Information Officer
Steven Barnard | Chief Technology Officer
Scott Davies | Chief Legal Officer & Secretary -
How many employees does ILMN have?
-
Number of ILMN employees currently stands at 8600. ILMN operates from 5200 Illumina Way, San Diego, CA 92122, US.
-
Link for ILMN official website?
-
Official Website of ILMN is: https://www.illumina.com
-
How do I contact ILMN?
-
ILMN could be contacted at phone #858 202 4500 and can also be accessed through its website. ILMN operates from 5200 Illumina Way, San Diego, CA 92122, US.
-
How many shares of ILMN are traded daily?
-
The average number of ILMN shares traded daily for last 3 months was 1.85M.
-
What is the market cap of ILMN currently?
-
The market value of ILMN currently stands at $28.45B with its latest stock price at $188.031